Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis

Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis

Aim: To assess the ability of signature metabolites alone, or in combination with the model for end-stage liver disease-Na (MELD-Na) score to predict mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. Materials & methods: Plasma metaboli...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayse L Mindikoglu, Cristian Coarfa, Antone R Opekun, Vijay H Shah, Juan P Arab, Konstantinos N Lazaridis, Nagireddy Putluri, Chandrashekar R Ambati, Matthew J Robertson, Sridevi Devaraj, Prasun K Jalal, Abbas Rana, John A Goss, Thomas C Dowling, Matthew R Weir, Stephen L Seliger, Jean-Pierre Raufman, David W Bernard, John M Vierling
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Future Science OA
Subjects:
biomarker
cirrhosis
liver transplantation
MELD-Na score
metabolite
metabolomics
Online Access:https://www.future-science.com/doi/10.2144/fsoa-2019-0124
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To assess the ability of signature metabolites alone, or in combination with the model for end-stage liver disease-Na (MELD-Na) score to predict mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. Materials & methods: Plasma metabolites were detected using ultrahigh-performance liquid chromatography/tandem mass spectrometry in 39 patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. Mortality was predicted using Cox proportional hazards regression and time-dependent receiver operating characteristic curve analyses. Results: The top five metabolites with significantly greater accuracy than the MELD-Na score (area under the receiver operating characteristic curve [AUROC] = 0.7591) to predict 1-year mortality were myo-inositol (AUROC = 0.9537), N-acetylputrescine (AUROC = 0.9018), trans-aconitate (AUROC = 0.8880), erythronate (AUROC = 0.8345) and N6-carbamoylthreonyladenosine (AUROC = 0.8055). Several combined MELD-Na-metabolite models increased the accuracy of predicted 1-year mortality substantially (AUROC increased from 0.7591 up to 0.9392). Conclusion: Plasma metabolites have the potential to enhance the accuracy of mortality predictions, minimize underestimates of mortality in patients with cirrhosis and low MELD-Na scores, and promote equitable allocation of donor livers.
ISSN:2056-5623

Similar Items